Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of GT818 monotherapy in advanced malignant tumors
CTR20262764Phase 2Active
- Sponsor
- Gluetacs Therapeutics
- Start
- Aug 2026
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of GT818 in Non-hematologic malignancy, sponsored by Gluetacs Therapeutics. Started Aug 2026; status: active.
02
Drugs
GT818
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on CTR20262764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262764.